Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature
1. The renal vasodilatory effect of YM435 was used as an index of its dopamine DA1 receptor agonist activity and compared with that of dopamine in pentobarbital-anesthetized dogs. 2. Intrarenal arterial administration of YM435 (0.1 to 10 micrograms) and dopamine (1 to 100 micrograms) produced a dose...
Gespeichert in:
| Veröffentlicht in: | General pharmacology 1997-08, Vol.29 (2), p.229-232 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 2 |
| container_start_page | 229 |
| container_title | General pharmacology |
| container_volume | 29 |
| creator | YATSU, T UCHIDA, W INAGAKI, O TANAKA, A TAKENAKA, T |
| description | 1. The renal vasodilatory effect of YM435 was used as an index of its dopamine DA1 receptor agonist activity and compared with that of dopamine in pentobarbital-anesthetized dogs. 2. Intrarenal arterial administration of YM435 (0.1 to 10 micrograms) and dopamine (1 to 100 micrograms) produced a dose-dependent increase in renal blood flow. The doses of YM435 and dopamine required to cause a 30-ml/min increase in renal blood flow were 2.0 and 26.8 micrograms intra-arterially (IA), respectively. YM435 was therefore 13 times more potent than dopamine in this effect. 3. The selective dopamine DA1 receptor antagonist, SCH 23390, but not the selective dopamine DA2 receptor antagonist, nemonapride, caused dose-dependent, parallel shifts to the right in the dose-responsive curve of YM435. 4. The present results demonstrate that YM435 is a potent and selective dopamine DA1 receptor agonist. |
| doi_str_mv | 10.1016/S0306-3623(96)00402-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79185698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79185698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c248t-bed8fe99349e511e715adb4a6dbb8bf45730d3af17624a27e95926de519e912f3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EKqXwCZW8QAgWAT9iJ15WLS-pqAtgwcpykgkE5YXtVOrfk7RRV7OYc-9oDkJzSu4pofLhnXAiAy4Zv1XyjpCQsCA-QVMaRyoghNJTND0i5-jCuV9CCBOMTdBEMUEVCados2paUxU14NWCYgsptL6x2Hw3deE8NqkvtoXf4SbHX28hF7iosf8BnJp6CFmoTYm3xqVdaXxn4RKd5aZ0cDXOGfp8evxYvgTrzfPrcrEOUhbGPkggi3NQiocKBKUQUWGyJDQyS5I4yUMRcZJxk9NIstCwCJRQTGY9q0BRlvMZujn0trb568B5XRUuhbI0NTSd05GisZAq7kFxAFPbOGch160tKmN3mhI9iNR7kXqwpJXUe5F6yM3HA11SQXZMjeb6_fW47583ZW5NnRbuiLFI9t2K_wM-9HoO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79185698</pqid></control><display><type>article</type><title>Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>YATSU, T ; UCHIDA, W ; INAGAKI, O ; TANAKA, A ; TAKENAKA, T</creator><creatorcontrib>YATSU, T ; UCHIDA, W ; INAGAKI, O ; TANAKA, A ; TAKENAKA, T</creatorcontrib><description>1. The renal vasodilatory effect of YM435 was used as an index of its dopamine DA1 receptor agonist activity and compared with that of dopamine in pentobarbital-anesthetized dogs. 2. Intrarenal arterial administration of YM435 (0.1 to 10 micrograms) and dopamine (1 to 100 micrograms) produced a dose-dependent increase in renal blood flow. The doses of YM435 and dopamine required to cause a 30-ml/min increase in renal blood flow were 2.0 and 26.8 micrograms intra-arterially (IA), respectively. YM435 was therefore 13 times more potent than dopamine in this effect. 3. The selective dopamine DA1 receptor antagonist, SCH 23390, but not the selective dopamine DA2 receptor antagonist, nemonapride, caused dose-dependent, parallel shifts to the right in the dose-responsive curve of YM435. 4. The present results demonstrate that YM435 is a potent and selective dopamine DA1 receptor agonist.</description><identifier>ISSN: 0306-3623</identifier><identifier>EISSN: 1879-0011</identifier><identifier>DOI: 10.1016/S0306-3623(96)00402-8</identifier><identifier>PMID: 9251904</identifier><identifier>CODEN: GEPHDP</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Animals ; Biological and medical sciences ; Cardiovascular system ; Dogs ; Dopamine - pharmacology ; Dopamine Agonists - pharmacology ; Female ; Fenoldopam - pharmacology ; Isoquinolines - pharmacology ; Kidney - blood supply ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Regional Blood Flow - drug effects ; Tetrahydroisoquinolines ; Vasodilator Agents - pharmacology ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>General pharmacology, 1997-08, Vol.29 (2), p.229-232</ispartof><rights>1997 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c248t-bed8fe99349e511e715adb4a6dbb8bf45730d3af17624a27e95926de519e912f3</citedby><cites>FETCH-LOGICAL-c248t-bed8fe99349e511e715adb4a6dbb8bf45730d3af17624a27e95926de519e912f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2760169$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9251904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YATSU, T</creatorcontrib><creatorcontrib>UCHIDA, W</creatorcontrib><creatorcontrib>INAGAKI, O</creatorcontrib><creatorcontrib>TANAKA, A</creatorcontrib><creatorcontrib>TAKENAKA, T</creatorcontrib><title>Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature</title><title>General pharmacology</title><addtitle>Gen Pharmacol</addtitle><description>1. The renal vasodilatory effect of YM435 was used as an index of its dopamine DA1 receptor agonist activity and compared with that of dopamine in pentobarbital-anesthetized dogs. 2. Intrarenal arterial administration of YM435 (0.1 to 10 micrograms) and dopamine (1 to 100 micrograms) produced a dose-dependent increase in renal blood flow. The doses of YM435 and dopamine required to cause a 30-ml/min increase in renal blood flow were 2.0 and 26.8 micrograms intra-arterially (IA), respectively. YM435 was therefore 13 times more potent than dopamine in this effect. 3. The selective dopamine DA1 receptor antagonist, SCH 23390, but not the selective dopamine DA2 receptor antagonist, nemonapride, caused dose-dependent, parallel shifts to the right in the dose-responsive curve of YM435. 4. The present results demonstrate that YM435 is a potent and selective dopamine DA1 receptor agonist.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Dogs</subject><subject>Dopamine - pharmacology</subject><subject>Dopamine Agonists - pharmacology</subject><subject>Female</subject><subject>Fenoldopam - pharmacology</subject><subject>Isoquinolines - pharmacology</subject><subject>Kidney - blood supply</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Regional Blood Flow - drug effects</subject><subject>Tetrahydroisoquinolines</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0306-3623</issn><issn>1879-0011</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EKqXwCZW8QAgWAT9iJ15WLS-pqAtgwcpykgkE5YXtVOrfk7RRV7OYc-9oDkJzSu4pofLhnXAiAy4Zv1XyjpCQsCA-QVMaRyoghNJTND0i5-jCuV9CCBOMTdBEMUEVCados2paUxU14NWCYgsptL6x2Hw3deE8NqkvtoXf4SbHX28hF7iosf8BnJp6CFmoTYm3xqVdaXxn4RKd5aZ0cDXOGfp8evxYvgTrzfPrcrEOUhbGPkggi3NQiocKBKUQUWGyJDQyS5I4yUMRcZJxk9NIstCwCJRQTGY9q0BRlvMZujn0trb568B5XRUuhbI0NTSd05GisZAq7kFxAFPbOGch160tKmN3mhI9iNR7kXqwpJXUe5F6yM3HA11SQXZMjeb6_fW47583ZW5NnRbuiLFI9t2K_wM-9HoO</recordid><startdate>199708</startdate><enddate>199708</enddate><creator>YATSU, T</creator><creator>UCHIDA, W</creator><creator>INAGAKI, O</creator><creator>TANAKA, A</creator><creator>TAKENAKA, T</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199708</creationdate><title>Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature</title><author>YATSU, T ; UCHIDA, W ; INAGAKI, O ; TANAKA, A ; TAKENAKA, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c248t-bed8fe99349e511e715adb4a6dbb8bf45730d3af17624a27e95926de519e912f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Dogs</topic><topic>Dopamine - pharmacology</topic><topic>Dopamine Agonists - pharmacology</topic><topic>Female</topic><topic>Fenoldopam - pharmacology</topic><topic>Isoquinolines - pharmacology</topic><topic>Kidney - blood supply</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Regional Blood Flow - drug effects</topic><topic>Tetrahydroisoquinolines</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>online_resources</toplevel><creatorcontrib>YATSU, T</creatorcontrib><creatorcontrib>UCHIDA, W</creatorcontrib><creatorcontrib>INAGAKI, O</creatorcontrib><creatorcontrib>TANAKA, A</creatorcontrib><creatorcontrib>TAKENAKA, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>General pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YATSU, T</au><au>UCHIDA, W</au><au>INAGAKI, O</au><au>TANAKA, A</au><au>TAKENAKA, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature</atitle><jtitle>General pharmacology</jtitle><addtitle>Gen Pharmacol</addtitle><date>1997-08</date><risdate>1997</risdate><volume>29</volume><issue>2</issue><spage>229</spage><epage>232</epage><pages>229-232</pages><issn>0306-3623</issn><eissn>1879-0011</eissn><coden>GEPHDP</coden><abstract>1. The renal vasodilatory effect of YM435 was used as an index of its dopamine DA1 receptor agonist activity and compared with that of dopamine in pentobarbital-anesthetized dogs. 2. Intrarenal arterial administration of YM435 (0.1 to 10 micrograms) and dopamine (1 to 100 micrograms) produced a dose-dependent increase in renal blood flow. The doses of YM435 and dopamine required to cause a 30-ml/min increase in renal blood flow were 2.0 and 26.8 micrograms intra-arterially (IA), respectively. YM435 was therefore 13 times more potent than dopamine in this effect. 3. The selective dopamine DA1 receptor antagonist, SCH 23390, but not the selective dopamine DA2 receptor antagonist, nemonapride, caused dose-dependent, parallel shifts to the right in the dose-responsive curve of YM435. 4. The present results demonstrate that YM435 is a potent and selective dopamine DA1 receptor agonist.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>9251904</pmid><doi>10.1016/S0306-3623(96)00402-8</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-3623 |
| ispartof | General pharmacology, 1997-08, Vol.29 (2), p.229-232 |
| issn | 0306-3623 1879-0011 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79185698 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Biological and medical sciences Cardiovascular system Dogs Dopamine - pharmacology Dopamine Agonists - pharmacology Female Fenoldopam - pharmacology Isoquinolines - pharmacology Kidney - blood supply Male Medical sciences Pharmacology. Drug treatments Regional Blood Flow - drug effects Tetrahydroisoquinolines Vasodilator Agents - pharmacology Vasodilator agents. Cerebral vasodilators |
| title | Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A11%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dopamine%20DA1%20receptor%20agonist%20activity%20of%20YM435%20in%20the%20canine%20renal%20vasculature&rft.jtitle=General%20pharmacology&rft.au=YATSU,%20T&rft.date=1997-08&rft.volume=29&rft.issue=2&rft.spage=229&rft.epage=232&rft.pages=229-232&rft.issn=0306-3623&rft.eissn=1879-0011&rft.coden=GEPHDP&rft_id=info:doi/10.1016/S0306-3623(96)00402-8&rft_dat=%3Cproquest_cross%3E79185698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79185698&rft_id=info:pmid/9251904&rfr_iscdi=true |